Nov 02, 2013 - 1:54 pm
The first drug to target a mutation common to all cancers goes to trial soon in the US and UK, Stanford and Oxford. Solid cancers in one trial, AML in the other. Trial headed by stem cell pioneer Irving Weissman of Stanford Univerity. Many peer reviewed journal papers are mentioned at below link for review. Good luck!